Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
4 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Tiziana Life Sciences Ltd.’s names, not what it holds today.
Patents granted
4
4 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and none in 2023
Applications published
15
1 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Tiziana Life Sciences PLC its own name
named as the applicant on its applications, in GB
14 publishedTiziana Life Sciences PLC its own name
GB, as the owner printed on each patent
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| May 7, 2024 | 11,975,111 | Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia | Pharmaceuticals | Tiziana Life Sciences PLC |
| Apr 13, 2021 | 10,973,773 | Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia | Pharmaceuticals | Tiziana Life Sciences PLC |
| Sep 1, 2020 | 10,758,541 | Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer | Pharmaceuticals | Tiziana Life Sciences PLC |
| Jun 23, 2020 | 10,688,186 | Anti-CD3 antibody formulations | Pharmaceuticals | Tiziana Life Sciences PLC |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Jul 17, 2025 | 2025/0228946 | ANTI-CD3 ANTIBODY FORMULATIONS | Pharmaceuticals | Tiziana Life Sciences PLC |
| Dec 26, 2024 | 2024/0425591 | METHODS OF SUPPRESSING MICROGLIAL ACTIVATION | Pharmaceuticals | Tiziana Life Sciences PLC |
| Oct 24, 2024 | 2024/0350497 | COMBINATION THERAPY FOR THE TREATMENT OF PAN-KRAS MUTATED CANCERS | Pharmaceuticals | Tiziana Life Sciences PLC |
| Aug 29, 2024 | 2024/0285632 | FORMULATIONS OF MILCICLIB AND THERAPEUTIC COMBINATIONS OF THE SAME FOR USE IN THE TREATMENT OF CANCER | Pharmaceuticals | Tiziana Life Sciences PLC |
| Nov 16, 2023 | 2023/0365689 | NASAL FORMULATIONS OF FORALUMAB | Pharmaceuticals | Tiziana Life Sciences PLC |
| Jul 20, 2023 | 2023/0227555 | CD-3 ANTIBODIES FOR THE TREATMENT OF CORONAVIRUS | Pharmaceuticals | Tiziana Life Sciences PLC |
| Jun 22, 2023 | 2023/0190804 | COMPOSITIONS AND METHODS FOR AUGMENTING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES | Medical technology | Tiziana Life Sciences PLC |
| Oct 20, 2022 | 2022/0332822 | SUBCUTANEOUS ADMINISTRATION OF ANTIBODIES FOR THE TREATMENT OF DISEASE | Pharmaceuticals | Tiziana Life Sciences PLC |
| Jan 13, 2022 | 2022/0008533 | COMPOSITION AND METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES | Pharmaceuticals | Tiziana Life Sciences PLC |
| Sep 16, 2021 | 2021/0284743 | COMPOSITIONS OF IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOF | Pharmaceuticals | Tiziana Life Sciences PLC |
What it applied for, 2024 to 2025: Pharmaceuticals 4.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.